Sep 13,2023

Lunit's AI-Powered Mammography Analysis Solution Achieves Comparable Diagnostic Performance with Human Readers

Lunit has unveiled the results of a collaborative study with Dr. Yan Chen, Ph.D., professor of digital screening at the University of Nottingham, United Kingdom. The study, recently published in Radiology, demonstrates that Lunit's AI-powered mammography analysis solution, Lunit INSIGHT MMG, matches the diagnostic performance of human readers. The study, which involved comparing Lunit's solution with assessments by 552 human readers, represents a significant milestone in the field of medical imaging and the future of breast cancer detection.  Conducted retrospectively, the study evaluated two PERFORMS test sets, each consisting of 60 challenging cases from the NHSBSP (National Health Service Breast Screening Program), over a three-year period. Human readers assessed these cases between May 2018 and March 2021, while Lunit's AI-powered mammography analysis solution evaluated them in 2022.  In the study, no significant difference was observed in the AUC (area under the ROC curve) between Lunit's AI-powered mammography analysis solution (0.93) and human readers (0.88), demonstrating the solution's ability to excel in breast cancer detection.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 11,2023

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women. Utilizing Lunit INSIGHT MMG, an FDA-cleared and CE-marked AI solution for mammography analysis, this research backs AI's potential to replace one human reader under Europe's double reading guideline and underscores its capacity to alleviate the strain on radiologists. Lunit INSIGHT MMG, collaborating with a single radiologist, exhibited a superior Cancer Detection Rate (CDR) of 4.7 per 1000, surpassing the traditional two-radiologist approach with a CDR of 4.5 per 1000. The study also showed a significant decline in recall rates (RR) with AI, both in collaboration with one radiologist (RR 2.8, 4.44% decrease) and when operating independently (RR 1.55, 47.1% decrease), compared to the double reading system (RR 2.93).

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 23,2022

Lunit Partners with CARPL.ai to Accelerate AI-Powered Medical Imaging Across Major Overseas Channels

Lunit announced that it signed a global distribution agreement with CARPL.ai, an end-to-end healthcare technology platform that enables the development, validation, and deployment of AI solutions across clinical workflows. Under the agreement, Lunit will deliver Lunit INSIGHT CXR, an AI solution for chest x-ray image analysis, and Lunit INSIGHT MMG, an AI solution for mammography analysis, through CARPL’s platform across five countries: U.S., Australia, Brazil, India, and Singapore.  Through CARPL’s interface, healthcare providers can seamlessly access Lunit’s AI solution suite for radiology, thereby improving access, affordability, and quality of medical care globally.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 21,2022

Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified

Lunit (KRX: 328130.KQ), a global provider of AI-powered cancer solutions, today announced that its AI solution suite for radiology, Lunit INSIGHT, has received the CE marking under Europe’s newest Medical Device Regulation (MDR). The Lunit INSIGHT product line also received the UK Conformity Assessed (UKCA) marking, obtaining commercial approval across both the UK and Europe. Among the Lunit INSIGHT suite, two products received the MDR CE and UKCA certifications: Lunit INSIGHT CXR, an AI solution for chest x-ray analysis, and Lunit INSIGHT MMG, an AI solution for mammography analysis.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 21,2022

AI-based Cancer Solution Pioneer Lunit Makes Market Debut

Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker “A32813”. Lunit’s initial public offering of 1,215,800 shares of its common stock was priced at KRW 30,000 (US$ 23) apiece. Shares closed at the upper limit price, KRW 40,000 (US$ 30.5), surging 29.87% in its debut.  Lunit expects to raise approximately KRW 36.4 billion (US$ 28 million).

View Analyst & Ambassador Comments
Go to original news
Jun 20,2022

Lunit AI Solution for Radiology Receives Health Canada Nod for Commercial Use

Lunit today announced that it received commercial approval in Canada for Lunit INSIGHT, the company’s AI solution suite for radiology. On June 14, Canadian medical device regulator Health Canada issued class 2 medical licenses for Lunit’s AI solution for chest x-ray, ‘Lunit INSIGHT CXR’ and ‘Lunit INSIGHT MMG,’ AI solution for mammography. 

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 28,2020

Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions

Lunit, a South Korean medical AI software company, announced a partnership with Emergent Connect, a leading provider of cloud-based PACS software. This partnership will bring AI solutions to Emergent Connect’s imaging cloud customer base, allowing AI to be more easily accessible to its clients. Emergent Connect manages millions of imaging records per year and helps thousands of healthcare professionals across hospitals, imaging centers and clinics provide the best patient care possible. Through this collaboration, healthcare centers using Emergent Connect software will be able to experience cutting-edge AI solutions without additional installation or configuration.

 

 

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 14,2020

Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry

Lunit, a leading medical AI startup, today announced the expansion of its collaboration with GE Healthcare. This collaboration between GE Healthcare and Lunit will help make AI algorithms more accessible to clinicians, alleviate clinical strain and streamline workflows – supporting better patient outcomes. This collaboration between GE Healthcare and Lunit is one of the first of its kind to bring commercially available AI products from a medical AI startup to an existing X-ray equipment manufacturer – making Lunit INSIGHT CXR available via Thoracic Care Suite to GE Healthcare’s thousands of global fixed, mobile, and R&F x-ray customers at point of sale. Lunit INSIGHT CXR is CE marked and is commercially available in European Economic Area and UK.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 25,2018

Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico

Lunit’s medical AI solution for chest radiography and mammography, Lunit INSIGHT, will be integrated into Fujifilm Synapse PACS system, which will then be evaluated by 20 radiologists in Salud Digna, one of the largest diagnostic service providers in Mexico. Upon the evaluation, Lunit and FUJIFILM Medical Systems USA, Inc. will seek to further develop the application and technology for more effective implementation on site. The project also includes an evaluation of worklist prioritization feature which could help to improve productivity in diagnosis.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 18,2021

TrialJectory Survey Exposes Significant Gap in Much-Needed Genetic Testing Among Cancer Patients

 TrialJectory (known as Leal Health now), an AI-powered, decision-making platform that connects cancer patients to advanced treatment options and helps to accelerate clinical research timelines, announced today results from a proprietary survey highlighting that, while an overwhelming majority of cancer patients surveyed (90 percent) understand the importance of genetic testing for achieving better clinical outcomes, less than half (46 percent) reported having undergone Next-Generation Sequencing (NGS), a genetic test used to identify novel cancer mutations and familial cancer mutation carriers. NGS testing is used to advance personalized cancer treatment and has proven in recent years to be a sound method for effectively capturing a large amount of genomic information about cancer. 

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY